Employer record · Watertown, MA · FY2024–FY2026

Diagonal Therapeutics, Inc.

    Certified LCAs
    3
    FY2024–FY2026
    USCIS approvals
    2
    2 new employment
    Denial rate
    0.0%
    FY2024–FY2026
    Median wage offered
    $100k
    certified LCAs

    Jobs not indexed yet

    Does Diagonal Therapeutics, Inc. sponsor H-1B visas?

    Yes — by its record, Diagonal Therapeutics, Inc. is a small-scale H-1B sponsor: it filed 3 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 2 USCIS H-1B petition approvals (2 for new employment). Its latest certified LCA in our data was decided Apr 24, 2026. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.

    Updated · DOL OFLC LCA disclosure + USCIS H-1B Employer Data Hub

    Filings by fiscal year

    Certified LCAs per U.S. government fiscal year (Oct–Sep); the slim bar is USCIS petition approvals (new + continuing), the bottom row their approval rate.

    Diagonal Therapeutics, Inc. certified LCAs by fiscal year
    Fiscal yearcertified LCAsUSCIS approvalsApproval rate
    FY2411100%
    FY2621100%

    Occupations sponsored

    Occupation (SOC)LCAsMedian wage
    Biochemists and Biophysicists 19-10211$100k
    Molecular and Cellular Biologists 19-10291$115k
    Biological Technicians 19-40211$90k

    Most-filed job titles

    1. Bioinformatics Scientist1$115k
    2. Senior Research Associate1$90k
    3. Scientist1$100k

    LCAs per title and median wage offered.

    Where the jobs were

    1. Massachusetts3 LCAs

    We haven't indexed Diagonal Therapeutics' jobs yet

    We read jobs straight from employers' own career sites and haven't added Diagonal Therapeutics' yet. Its H-1B record on this page comes from public DOL and USCIS data and is not affected.

    Also filed as

    • Diagonal Therapeutics, Inc. (LCA)
    • DIAGONAL THERAPEUTICS INC (USCIS)

    Diagonal Therapeutics, Inc. H-1B: questions people ask

    Does Diagonal Therapeutics, Inc. sponsor H-1B visas?

    Yes — by its record, Diagonal Therapeutics, Inc. is a small-scale H-1B sponsor: it filed 3 certified Labor Condition Applications (LCAs) in FY2024–FY2026 and received 2 USCIS H-1B petition approvals (2 for new employment). Its latest certified LCA in our data was decided Apr 24, 2026. Past filings are history, not a promise: they do not mean the employer will sponsor you or a given role.

    Is Diagonal Therapeutics, Inc. still sponsoring H-1B in 2026?

    Diagonal Therapeutics, Inc. had 2 certified LCAs in FY2026 (Oct 2025–Sep 2026), more than the 0 in FY2025. The latest one in our data was decided Apr 24, 2026. An LCA is filed before a petition, so it shows recent intent to hire on H-1B, not a hire.

    How many H-1B petitions does Diagonal Therapeutics, Inc. get approved?

    USCIS recorded 2 approvals (2 for new employment, the rest continuing employment such as extensions and transfers) and 0 denials for Diagonal Therapeutics, Inc. in FY2024–FY2026 — a denial rate of 0.0%. Source: USCIS H-1B Employer Data Hub (first decisions).

    What is the H-1B salary at Diagonal Therapeutics, Inc.?

    The median wage offered on Diagonal Therapeutics, Inc.'s certified LCAs in FY2024–FY2026 was $100k a year. By job title: Bioinformatics Scientist $115k (1 LCAs), Senior Research Associate $90k (1 LCAs) and Scientist $100k (1 LCAs). LCA wages are the pay the employer attested to; actual pay can be higher.

    Which jobs does Diagonal Therapeutics, Inc. sponsor for H-1B?

    Its certified LCAs in FY2024–FY2026 were mostly for Biochemists and Biophysicists (1), Molecular and Cellular Biologists (1) and Biological Technicians (1).

    Where are Diagonal Therapeutics, Inc.'s H-1B jobs?

    By worksite on its certified LCAs (FY2024–FY2026): Massachusetts (3).

    Is Diagonal Therapeutics, Inc. an H-1B dependent employer?

    No — its recent LCAs do not declare it H-1B dependent.

    Does Diagonal Therapeutics, Inc. have open jobs?

    We read jobs straight from employers' own career sites and haven't added Diagonal Therapeutics' yet.